Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations. The median investigator-assessed progression-free ...

in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.

Discontinuation of the CDK4/6 inhibitor occurred in 1% of patients in both arms of the trial. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a circulating tumor ...

Camizestrant plus CDK4/6 inhibitors improved progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to AI and CDK4/6 inhibitors. The SERENA-6 trial used ...

unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. and China.

After the tumor was formed, the nude mice were given myricetin gavage every other day. The tumor was weighed, and HE and immunohistochemistry staining were performed. Tumor tissue from nude mice was ...

Reliable predictive biomarkers for immunotherapy response have eluded clinicians, who currently rely on PD-L1 immunohistochemistry, tumor mutational burden, and microsatellite stability tests ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify ...

today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists ...